See more : Adani Power Limited (ADANIPOWER.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Astellas Pharma Inc. (ALPMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astellas Pharma Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- PT Greenwood Sejahtera Tbk (GWSA.JK) Income Statement Analysis – Financial Results
- GreenBee, Inc. (3913.T) Income Statement Analysis – Financial Results
- Concert Pharmaceuticals, Inc. (CNCE) Income Statement Analysis – Financial Results
- HB Portfolio Limited (HBPOR.BO) Income Statement Analysis – Financial Results
- D and O Home Collection Group Co., Ltd. (002798.SZ) Income Statement Analysis – Financial Results
Astellas Pharma Inc. (ALPMY)
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,603.67B | 1,518.62B | 1,296.16B | 1,249.53B | 1,300.84B | 1,306.35B | 1,300.32B | 1,311.67B | 1,372.71B | 1,247.26B | 1,139.91B | 1,005.61B |
| Cost of Revenue | 292.49B | 326.79B | 281.29B | 269.83B | 297.90B | 327.26B | 330.09B | 356.34B | 377.98B | 333.20B | 330.63B | 324.13B |
| Gross Profit | 1,311.19B | 1,191.83B | 1,014.87B | 979.70B | 1,002.94B | 979.09B | 970.23B | 955.33B | 994.72B | 914.06B | 809.28B | 681.49B |
| Gross Profit Ratio | 81.76% | 78.48% | 78.30% | 78.41% | 77.10% | 74.95% | 74.61% | 72.83% | 72.46% | 73.29% | 71.00% | 67.77% |
| Research & Development | 294.20B | 276.13B | 246.01B | 224.49B | 224.23B | 208.68B | 220.78B | 208.13B | 225.67B | 206.60B | 191.50B | 181.96B |
| General & Administrative | 740.11B | 630.27B | 548.84B | 504.32B | 499.30B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 259.16B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.50B |
| SG&A | 740.11B | 630.27B | 548.84B | 504.32B | 499.30B | 490.26B | 478.21B | 470.78B | 498.48B | 452.52B | 397.02B | 345.66B |
| Other Expenses | 251.36B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1,285.67B | 906.40B | 794.85B | 728.81B | 723.52B | 698.95B | 698.99B | 678.91B | 724.15B | 726.32B | 688.90B | 558.62B |
| Cost & Expenses | 1,578.15B | 1,233.19B | 1,076.14B | 998.63B | 1,021.42B | 1,026.21B | 1,029.08B | 1,035.25B | 1,102.13B | 1,059.52B | 1,019.53B | 882.75B |
| Interest Income | 11.46B | 5.21B | 794.00M | 683.00M | 2.16B | 2.69B | 1.65B | 978.00M | 985.00M | 1.94B | 1.59B | 1.81B |
| Interest Expense | 12.01B | 3.62B | 4.95B | 2.34B | 3.00B | 1.30B | 1.31B | 1.33B | 1.26B | 3.08B | 1.66B | 1.82B |
| Depreciation & Amortization | 157.84B | 105.74B | 79.68B | 72.65B | 66.40B | 63.46B | 64.86B | 63.79B | 69.19B | 65.47B | 64.30B | 57.86B |
| EBITDA | 194.81B | 246.88B | 241.52B | 220.31B | 314.75B | 313.73B | 284.76B | 347.54B | 332.59B | 258.24B | 187.94B | 180.10B |
| EBITDA Ratio | 12.15% | 25.76% | 23.12% | 25.89% | 26.58% | 26.30% | 25.85% | 25.94% | 24.75% | 23.44% | 21.70% | 21.05% |
| Operating Income | 25.52B | 285.43B | 220.02B | 250.90B | 279.42B | 280.14B | 271.24B | 276.42B | 270.58B | 226.87B | 183.09B | 153.87B |
| Operating Income Ratio | 1.59% | 18.80% | 16.97% | 20.08% | 21.48% | 21.44% | 20.86% | 21.07% | 19.71% | 18.19% | 16.06% | 15.30% |
| Total Other Income/Expenses | -549.00M | -668.00M | 711.00M | 8.80B | 3.02B | 5.06B | 4.86B | 5.35B | -8.81B | -37.19B | 5.17B | 3.08B |
| Income Before Tax | 24.97B | 131.10B | 156.40B | 144.85B | 247.01B | 248.97B | 218.11B | 281.77B | 261.77B | 189.68B | 121.97B | 124.67B |
| Income Before Tax Ratio | 1.56% | 8.63% | 12.07% | 11.59% | 18.99% | 19.06% | 16.77% | 21.48% | 19.07% | 15.21% | 10.70% | 12.40% |
| Income Tax Expense | 7.92B | 33.65B | 32.80B | 24.73B | 49.94B | 26.70B | 53.43B | 63.07B | 68.08B | 53.83B | 31.10B | 41.82B |
| Net Income | 17.05B | 98.71B | 124.09B | 120.59B | 195.41B | 222.27B | 164.68B | 218.70B | 193.69B | 135.86B | 90.87B | 82.85B |
| Net Income Ratio | 1.06% | 6.50% | 9.57% | 9.65% | 15.02% | 17.01% | 12.66% | 16.67% | 14.11% | 10.89% | 7.97% | 8.24% |
| EPS | 9.47 | 54.24 | 67.08 | 64.93 | 104.15 | 115.05 | 81.11 | 103.69 | 89.75 | 61.40 | 40.39 | 36.03 |
| EPS Diluted | 9.47 | 54.09 | 67.05 | 64.90 | 104.08 | 114.94 | 81.02 | 103.55 | 89.62 | 61.40 | 40.39 | 36.03 |
| Weighted Avg Shares Out | 1.80B | 1.82B | 1.85B | 1.86B | 1.88B | 1.93B | 2.03B | 2.11B | 2.16B | 2.21B | 2.25B | 2.30B |
| Weighted Avg Shares Out (Dil) | 1.80B | 1.83B | 1.85B | 1.86B | 1.88B | 1.93B | 2.03B | 2.11B | 2.16B | 2.21B | 2.25B | 2.30B |
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Astellas Makes Announcement about Management Structure
Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Astellas Announces Strategic Collaboration with Mass General Brigham
US FDA declines to approve Astellas' gastric cancer drug
Source: https://incomestatements.info
Category: Stock Reports